Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.
Jim Cramer weighs in on Abbott, GlaxoSmithKline, Waste Management and more.
Shares decline after the company says a lung-cancer study it had been working on failed.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Shares of the New York City-based pharmaceutical giant are rising on Monday.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.